| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 17.74 mm | 17.74 mm | 17.74 mm | 17.74 mm | 17.74 mm | 17.74 mm |
| Cash burn (monthly) | 1.47 mm | (no burn) | 8.02 mm | 10.36 mm | 6.25 mm | 9.07 mm |
| Cash used (since last report) | 42.73 mm | n/a | 233.23 mm | 301.19 mm | 181.73 mm | 263.65 mm |
| Cash remaining | -24.99 mm | n/a | -215.49 mm | -283.45 mm | -163.98 mm | -245.90 mm |
| Runway (months of cash) | -17.0 | n/a | -26.9 | -27.4 | -26.2 | -27.1 |
| 13F holders | Current |
|---|---|
| Total holders | 3 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 92.27 mm |
| Total shares | 7.50 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Longitude Capital Partners II | 3.02 mm | $90.62 mm |
| Venrock Healthcare Capital Partners II | 2.98 mm | $1.65 mm |
| Frazier Life Sciences Public Fund | 1.50 mm | $0.00 |
| Proequities | 0.00 | $0.00 |
